1. Home
  2. NAK vs AMPH Comparison

NAK vs AMPH Comparison

Compare NAK & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

HOLD

Current Price

$2.02

Market Cap

1.2B

ML Signal

HOLD

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$26.84

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAK
AMPH
Founded
1983
1996
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
NAK
AMPH
Price
$2.02
$26.84
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$2.50
$31.00
AVG Volume (30 Days)
6.5M
380.2K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.27
Revenue
N/A
$723,305,000.00
Revenue This Year
N/A
$1.35
Revenue Next Year
N/A
$5.10
P/E Ratio
N/A
$11.95
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$20.39
52 Week High
$2.98
$39.01

Technical Indicators

Market Signals
Indicator
NAK
AMPH
Relative Strength Index (RSI) 49.42 53.45
Support Level $2.01 $26.26
Resistance Level $2.44 $27.44
Average True Range (ATR) 0.15 0.79
MACD -0.01 0.06
Stochastic Oscillator 21.70 74.12

Price Performance

Historical Comparison
NAK
AMPH

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: